Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
Stopped This study was terminated early due to manufacturer withdrawal of support (study medication) due to lack of enrollment.
Conditions
- Clear-Cell Renal Carcinoma
Interventions
- DRUG: rhIL-15
- BIOLOGICAL: Avelumab
Sponsor
National Cancer Institute (NCI)